Cargando…

One-year follow-up of patients with long-lasting post-herpetic neuralgia

BACKGROUND: Recent information on epidemiology and management of post-herpetic neuralgia (PHN), a painful complication of zoster, is scarce. METHODS: This study was conducted at the Pain Clinic of the Policlinico Tor Vergata, Rome, Italy, on eighty-five immunocompetent patients with a clinical diagn...

Descripción completa

Detalles Bibliográficos
Autores principales: Pica, Francesca, Gatti, Antonio, Divizia, Marco, Lazzari, Marzia, Ciotti, Marco, Sabato, Alessandro Fabrizio, Volpi, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226872/
https://www.ncbi.nlm.nih.gov/pubmed/25361823
http://dx.doi.org/10.1186/s12879-014-0556-6
_version_ 1782343683261071360
author Pica, Francesca
Gatti, Antonio
Divizia, Marco
Lazzari, Marzia
Ciotti, Marco
Sabato, Alessandro Fabrizio
Volpi, Antonio
author_facet Pica, Francesca
Gatti, Antonio
Divizia, Marco
Lazzari, Marzia
Ciotti, Marco
Sabato, Alessandro Fabrizio
Volpi, Antonio
author_sort Pica, Francesca
collection PubMed
description BACKGROUND: Recent information on epidemiology and management of post-herpetic neuralgia (PHN), a painful complication of zoster, is scarce. METHODS: This study was conducted at the Pain Clinic of the Policlinico Tor Vergata, Rome, Italy, on eighty-five immunocompetent patients with a clinical diagnosis of PHN. At enrollment (time 0, T0), the patients were interviewed by physicians to obtain demographic data and information about their zoster clinical history and underwent a blood test for VZV-DNA research. DN4 and SF-12 questionnaires were used to assess the neuropathic nature of pain and the overall health status, respectively. A one-year follow-up was planned for enrolled cases, who were visited at regular intervals of at least 3 months. RESULTS: At T0 all the patients were at least 6 months from the episode of acute zoster and still presented with intense pain (mean VAS =6.7; mean DN4 = 5.7). Using antivirals within 72 hours from the rash onset was associated to a significant reduction of pain at T0 (p = 0.006 vs untreated patients). Only 2.6% of patients treated with antivirals during acute zoster but 18.6% of the untreated ones presented with neuropathic pain at T12 (p =0.007), even though the two groups were similar at T0. VZV-DNA was found in 5 out of the 50 available blood samples. At the last follow-up visit, PCS and MCS scores of the PHN patients were found to be recovered over those of the historical age-matched healthy controls. Undesirable side effects of analgesic therapies were observed in 15.3 to 28.8% of the patients. CONCLUSIONS: Patients who six months after acute zoster still have significant neuropathic pain, have a high probability of suffering from chronic pain in the subsequent months/years. The initial antiviral treatment has a significant impact on the pain. Current strategies of analgesic therapy are effective to achieve relief of pain in PHN patients, but they are burdened with heavy and undesirable side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0556-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4226872
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42268722014-11-12 One-year follow-up of patients with long-lasting post-herpetic neuralgia Pica, Francesca Gatti, Antonio Divizia, Marco Lazzari, Marzia Ciotti, Marco Sabato, Alessandro Fabrizio Volpi, Antonio BMC Infect Dis Research Article BACKGROUND: Recent information on epidemiology and management of post-herpetic neuralgia (PHN), a painful complication of zoster, is scarce. METHODS: This study was conducted at the Pain Clinic of the Policlinico Tor Vergata, Rome, Italy, on eighty-five immunocompetent patients with a clinical diagnosis of PHN. At enrollment (time 0, T0), the patients were interviewed by physicians to obtain demographic data and information about their zoster clinical history and underwent a blood test for VZV-DNA research. DN4 and SF-12 questionnaires were used to assess the neuropathic nature of pain and the overall health status, respectively. A one-year follow-up was planned for enrolled cases, who were visited at regular intervals of at least 3 months. RESULTS: At T0 all the patients were at least 6 months from the episode of acute zoster and still presented with intense pain (mean VAS =6.7; mean DN4 = 5.7). Using antivirals within 72 hours from the rash onset was associated to a significant reduction of pain at T0 (p = 0.006 vs untreated patients). Only 2.6% of patients treated with antivirals during acute zoster but 18.6% of the untreated ones presented with neuropathic pain at T12 (p =0.007), even though the two groups were similar at T0. VZV-DNA was found in 5 out of the 50 available blood samples. At the last follow-up visit, PCS and MCS scores of the PHN patients were found to be recovered over those of the historical age-matched healthy controls. Undesirable side effects of analgesic therapies were observed in 15.3 to 28.8% of the patients. CONCLUSIONS: Patients who six months after acute zoster still have significant neuropathic pain, have a high probability of suffering from chronic pain in the subsequent months/years. The initial antiviral treatment has a significant impact on the pain. Current strategies of analgesic therapy are effective to achieve relief of pain in PHN patients, but they are burdened with heavy and undesirable side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0556-6) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-01 /pmc/articles/PMC4226872/ /pubmed/25361823 http://dx.doi.org/10.1186/s12879-014-0556-6 Text en © Pica et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pica, Francesca
Gatti, Antonio
Divizia, Marco
Lazzari, Marzia
Ciotti, Marco
Sabato, Alessandro Fabrizio
Volpi, Antonio
One-year follow-up of patients with long-lasting post-herpetic neuralgia
title One-year follow-up of patients with long-lasting post-herpetic neuralgia
title_full One-year follow-up of patients with long-lasting post-herpetic neuralgia
title_fullStr One-year follow-up of patients with long-lasting post-herpetic neuralgia
title_full_unstemmed One-year follow-up of patients with long-lasting post-herpetic neuralgia
title_short One-year follow-up of patients with long-lasting post-herpetic neuralgia
title_sort one-year follow-up of patients with long-lasting post-herpetic neuralgia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226872/
https://www.ncbi.nlm.nih.gov/pubmed/25361823
http://dx.doi.org/10.1186/s12879-014-0556-6
work_keys_str_mv AT picafrancesca oneyearfollowupofpatientswithlonglastingpostherpeticneuralgia
AT gattiantonio oneyearfollowupofpatientswithlonglastingpostherpeticneuralgia
AT diviziamarco oneyearfollowupofpatientswithlonglastingpostherpeticneuralgia
AT lazzarimarzia oneyearfollowupofpatientswithlonglastingpostherpeticneuralgia
AT ciottimarco oneyearfollowupofpatientswithlonglastingpostherpeticneuralgia
AT sabatoalessandrofabrizio oneyearfollowupofpatientswithlonglastingpostherpeticneuralgia
AT volpiantonio oneyearfollowupofpatientswithlonglastingpostherpeticneuralgia